摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-propyl-3-(chloroethyl)-5,6-dihydro-1,4-oxathiin

中文名称
——
中文别名
——
英文名称
2-propyl-3-(chloroethyl)-5,6-dihydro-1,4-oxathiin
英文别名
5-(1-Chloroethyl)-6-propyl-2,3-dihydro-1,4-oxathiine
2-propyl-3-(chloroethyl)-5,6-dihydro-1,4-oxathiin化学式
CAS
——
化学式
C9H15ClOS
mdl
——
分子量
206.737
InChiKey
RLMRHHOLAWMWDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    34.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    1,2-二氯-4-庚酮2-巯基乙醇 在 PTS 、 PTSA 、 三乙胺 作用下, 以 甲苯 为溶剂, 以23%的产率得到2-propyl-3-(chloroethyl)-5,6-dihydro-1,4-oxathiin
    参考文献:
    名称:
    3-(2-Haloalkyl)-1,4-oxathiins and 2-(2-haloalkyl)-1,4-dithiins, and
    摘要:
    新型3-(2-卤代烷基)-1,4-噁嗪或2-(2-卤代烷基)-1,4-二硫噁嗪,可用于逆转或抑制哺乳动物体内白血病和肿瘤的生长。这些化合物的化学式如下:##STR1## 其中R.sub.1是含有最多4个碳原子、环己烷基或苯基的烷基基团;R.sub.2是氢或乙基;R.sub.3和R.sub.4分别是氢、甲基或乙基,当R.sub.3和R.sub.4中的一个是甲基或乙基时,另一个是氢;X是卤素;Y是氧或硫,当Y是硫时,R.sub.3和R.sub.4都是氢。以及含有这些化合物与药学上可接受的基本无毒载体混合物的药物组合物。
    公开号:
    US04822813A1
点击查看最新优质反应信息

文献信息

  • US4822813A
    申请人:——
    公开号:US4822813A
    公开(公告)日:1989-04-18
  • 3-(2-Haloalkyl)-1,4-oxathiins and 2-(2-haloalkyl)-1,4-dithiins, and
    申请人:Uniroyal Chemical Ltd./Uniroyal Chemical Ltee
    公开号:US04822813A1
    公开(公告)日:1989-04-18
    Novel 3-(2-haloalkyl)-1,4-oxathiins or 2-(2-haloalkyl)-1,4-dithiins, useful for regressing or inhibiting the growth of leukemia and tumors in mammals. The compounds have the formula.: ##STR1## wherein R.sub.1 is an alkyl group containing up to 4 carbon atoms, cyclohexyl or phenyl; R.sub.2 is hydrogen or ethyl; R.sub.3 and R.sub.4 are each hydrogen, methyl or ethyl, and when either R.sub.3 and R.sub.4 is methyl or ethyl, the other is hydrogen; X is halogen; and Y is oxygen or sulfur and when Y is sulfur, R.sub.3 and R.sub.4 are both hydrogen. and pharmaceutical compositions comprising said compounds in admixture with a pharmaceutically acceptable substantially non-toxic carrier.
    新型3-(2-卤代烷基)-1,4-噁嗪或2-(2-卤代烷基)-1,4-二硫噁嗪,可用于逆转或抑制哺乳动物体内白血病和肿瘤的生长。这些化合物的化学式如下:##STR1## 其中R.sub.1是含有最多4个碳原子、环己烷基或苯基的烷基基团;R.sub.2是氢或乙基;R.sub.3和R.sub.4分别是氢、甲基或乙基,当R.sub.3和R.sub.4中的一个是甲基或乙基时,另一个是氢;X是卤素;Y是氧或硫,当Y是硫时,R.sub.3和R.sub.4都是氢。以及含有这些化合物与药学上可接受的基本无毒载体混合物的药物组合物。
查看更多

同类化合物

6-乙氧基-2-甲基-5,6-二氢-1,4-氧硫杂环己二烯-3-羧酸 5,6-二氢-1,4-氧硫杂环己二烯-2-羧酸 5,6,7,8-四氢-4,7-二甲基-1,2-苯并氧硫杂环己二烯 2,2-二氧化物 2-甲基-5,6-二氢-1,4-氧硫杂环己二烯-3-甲酸 2-甲基-1,4-氧硫杂环己二烯-3-羧酸 1-(6-乙氧基-2-甲基-4-氧代-5,6-二氢-1,4-氧硫杂环己二烯-3-基)乙酮 1,4-苯并氧硫杂环己二烯4,4-二氧化物 1,4-氧硫杂环己二烯 1,4-噁噻英,2,3-二氢-5,6-二甲基- 1,2-苯并噁噻英,3,4-二氢- 1,2-氧硫杂环己二烯 methyl 6-chlorosulfonyl-3-methyl-1,2-benzoxathiin 2,2-dioxide ethyl benzo[e][1,2]oxathiine-3-carboxylate 2,2-dioxide N,N,N',N'-tetramethyl-N''-[2,2,2-trichloro-1-(5',6'-dihydro-2'-methyl-1',4'-oxathiin-3'-carboxamido)ethyl]phosphoric triamide 4-tert-butyl-1-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1H-1,2,3-triazole 2-amino-4a,5,6,7,8,8a-hexahydrobenzo[b][1,4]oxathiine-3-carbonitrile 2,3-dihydro-2-methyl-2,6-diphenyl-1,4-oxathiin 2-[1-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1H-1,2,3-triazol-4-yl]propan-2-ol 5,6-dihydro-[1,2]oxathiine 2,2-dioxide (+/-)-(2R,3R)-3-[(5-acetyl-6-methyl-2-prop-2-enyloxy-2H,3H-1,4-oxathiin-3-yl)methylthio]pentane-2,4-dione 2-propyl-3-(chloroethyl)-5,6-dihydro-1,4-oxathiin 3-(2-chlorobutyl)-5,6-dihydro-2-methyl-1,4-oxathiin 3-(2-chloroethyl)-5,6-dihydro-2-methyl-1,4-oxathiin 1-<5,6-dihydro-2-methyl-6-N-(2'-oxo-2',3',4',5'-tetrahydropyrrolo)-1,4-oxathiin-3-yl>ethanone 3-(2-chloroethyl)-5,6-dihydro-1,4-oxathiin 2-Butanone, 4-(4-hydroxy-2,2-dioxido-1,2-benzoxathiin-3-yl)-4-phenyl- Phosphorodithioic acid, S-2,3-dihydro-1,4-oxathiinyl O,O-dimethyl ester 4,7-Dimethyl-1,2,5,6,7,8-hexahydro-1-oxa-2-thianaphthalene 2,2-dioxide 4,5,6,7,8,9-hexahydro-1H-cyclohept[d][1,2]oxathiin-3-oxide 6,8-dichloro-1,2-benzoxathiine 2,2-dioxide 6-Morpholin-4-yl-2-phenyl-4,5,6,7-tetrahydro-9-oxa-1,8-dithia-3-aza-cyclopenta[a]naphthalene 8,8-dioxide 2-Phenyl-6-piperidin-1-yl-4,5,6,7-tetrahydro-9-oxa-1,8-dithia-3-aza-cyclopenta[a]naphthalene 8,8-dioxide ocimene sultone N,N-diisopropyl-3,4,5,6-tetrahydro-8-phenyl-1,2-oxathiino<5,6-g>benzothiazol-4-amine 2,2-dioxide N,N-dimethyl-3,4,5,6-tetrahydro-8-phenyl-1,2-oxathiino<5,6-g>benzothiazol-4-amine 2,2-dioxide 1,4-dimethyl-5,6,7,8-tetrahydro-benz[d][1,2]oxathiin-3,3-dioxide 2,2-dioxido-1,2-benzoxathiin-6-yl methanesulfonate (5,6-Dihydro-[1,4]oxathiin-2-yl)-acetic acid methyl ester acetic acid 2,2-dioxo-2H-2λ6-benzo[e][1,2]oxathiin-7-yl ester methanesulfonic acid 2,2-dioxo-2H-2λ6-benzo[e][1,2]oxathiin-7-yl ester acetic acid 2,2-dioxo-3,4-dihydro-2H-2λ6-benzo[e][1,2]oxathiin-7-yl ester methanesulfonic acid 2,2-dioxo-3,4-dihydro-2H-2λ6-benzo[e][1,2]oxathiin-7-yl ester ethyl 5,6-dihydro-2-trifluoromethyl-1,4-oxathiin-3-carboxylate 6-Phenyl-1,4-oxathiin-2-one 4-cyclopropyl-1-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1H-1,2,3-triazole 4-(N,N-Diethylamino)-3,4,10,11-tetrahydro-5H-benzo-cyclohepta-1,2-oxathiin-2,2-dioxid (2,2-Dioxo-2,3,4,5,6,7-hexahydro-1-oxa-2λ6-thia-dibenzo[a,c]cyclohepten-4-yl)-diethyl-amine 6-methyl-4-pyrrolidin-1-yl-3,4,5,6,7,8-hexahydro-[1,2]oxathiino[5,6-c]pyridine 2,2-dioxide 6-methyl-4-piperidin-1-yl-3,4,5,6,7,8-hexahydro-[1,2]oxathiino[5,6-c]pyridine 2,2-dioxide 1-(2,2-Dioxo-6-phenyl-3,4-dihydro-2H-2λ6-[1,2]oxathiin-4-yl)-piperidine